BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 25043693)

  • 1. Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma.
    Mar VJ; Wong SQ; Logan A; Nguyen T; Cebon J; Kelly JW; Wolfe R; Dobrovic A; McLean C; McArthur GA
    Pigment Cell Melanoma Res; 2014 Nov; 27(6):1117-25. PubMed ID: 25043693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage.
    Mar VJ; Wong SQ; Li J; Scolyer RA; McLean C; Papenfuss AT; Tothill RW; Kakavand H; Mann GJ; Thompson JF; Behren A; Cebon JS; Wolfe R; Kelly JW; Dobrovic A; McArthur GA
    Clin Cancer Res; 2013 Sep; 19(17):4589-98. PubMed ID: 23833303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF.
    Watson IR; Li L; Cabeceiras PK; Mahdavi M; Gutschner T; Genovese G; Wang G; Fang Z; Tepper JM; Stemke-Hale K; Tsai KY; Davies MA; Mills GB; Chin L
    Cancer Res; 2014 Sep; 74(17):4845-4852. PubMed ID: 25056119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
    Griewank KG; Westekemper H; Murali R; Mach M; Schilling B; Wiesner T; Schimming T; Livingstone E; Sucker A; Grabellus F; Metz C; Süsskind D; Hillen U; Speicher MR; Woodman SE; Steuhl KP; Schadendorf D
    Clin Cancer Res; 2013 Jun; 19(12):3143-52. PubMed ID: 23633454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAC1
    Lionarons DA; Hancock DC; Rana S; East P; Moore C; Murillo MM; Carvalho J; Spencer-Dene B; Herbert E; Stamp G; Damry D; Calado DP; Rosewell I; Fritsch R; Neubig RR; Molina-Arcas M; Downward J
    Cancer Cell; 2019 Jul; 36(1):68-83.e9. PubMed ID: 31257073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
    Krauthammer M; Kong Y; Ha BH; Evans P; Bacchiocchi A; McCusker JP; Cheng E; Davis MJ; Goh G; Choi M; Ariyan S; Narayan D; Dutton-Regester K; Capatana A; Holman EC; Bosenberg M; Sznol M; Kluger HM; Brash DE; Stern DF; Materin MA; Lo RS; Mane S; Ma S; Kidd KK; Hayward NK; Lifton RP; Schlessinger J; Boggon TJ; Halaban R
    Nat Genet; 2012 Sep; 44(9):1006-14. PubMed ID: 22842228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of BRAF and NRAS mutations in fast-growing melanomas.
    Nagore E; Hacker E; Martorell-Calatayud A; Traves V; Guillen C; Hayward NK; Whiteman D
    Pigment Cell Melanoma Res; 2013 May; 26(3):429-31. PubMed ID: 23448684
    [No Abstract]   [Full Text] [Related]  

  • 9. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
    Colombino M; Capone M; Lissia A; Cossu A; Rubino C; De Giorgi V; Massi D; Fonsatti E; Staibano S; Nappi O; Pagani E; Casula M; Manca A; Sini M; Franco R; Botti G; Caracò C; Mozzillo N; Ascierto PA; Palmieri G
    J Clin Oncol; 2012 Jul; 30(20):2522-9. PubMed ID: 22614978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NRAS and BRAF mutations in cutaneous melanoma and the association with MC1R genotype: findings from Spanish and Austrian populations.
    Hacker E; Nagore E; Cerroni L; Woods SL; Hayward NK; Chapman B; Montgomery GW; Soyer HP; Whiteman DC
    J Invest Dermatol; 2013 Apr; 133(4):1027-33. PubMed ID: 23096702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
    Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
    Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BRAF, NRAS and MC1R status in a prospective series of primary cutaneous melanoma.
    García-Casado Z; Traves V; Bañuls J; Niveiro M; Gimeno-Carpio E; Jimenez-Sanchez AI; Moragón M; Onrubia JA; Oliver V; Kumar R; Nagore E
    Br J Dermatol; 2015 Apr; 172(4):1128-31. PubMed ID: 25385688
    [No Abstract]   [Full Text] [Related]  

  • 13. Heterogeneity of BRAF, NRAS, and TERT Promoter Mutational Status in Multiple Melanomas and Association with MC1R Genotype: Findings from Molecular and Immunohistochemical Analysis.
    Pellegrini C; Di Nardo L; Cipolloni G; Martorelli C; De Padova M; Antonini A; Maturo MG; Del Regno L; Strafella S; Micantonio T; Leocata P; Peris K; Fargnoli MC
    J Mol Diagn; 2018 Jan; 20(1):110-122. PubMed ID: 29061376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dermoscopic criteria associated with BRAF and NRAS mutation status in primary cutaneous melanoma.
    Pozzobon FC; Puig-Butillé JA; González-Alvarez T; Carrera C; Aguilera P; Alos L; Badenas C; Grichnik JM; Malvehy J; Puig S
    Br J Dermatol; 2014 Oct; 171(4):754-9. PubMed ID: 24749938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization.
    Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M
    Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NRAS mutations are more prevalent than KIT mutations in melanoma of the female urogenital tract--a study of 24 cases from the Netherlands.
    van Engen-van Grunsven AC; Küsters-Vandevelde HV; De Hullu J; van Duijn LM; Rijntjes J; Bovée JV; Groenen PJ; Blokx WA
    Gynecol Oncol; 2014 Jul; 134(1):10-4. PubMed ID: 24802725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
    Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
    Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.
    Saroufim M; Habib RH; Gerges R; Saab J; Loya A; Amr SS; Sheikh S; Satti M; Oberkanins C; Khalifeh I
    Exp Mol Pathol; 2014 Dec; 97(3):315-20. PubMed ID: 25236573
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Varying Mutational Alterations in Multiple Primary Melanomas.
    Egberts F; Bohne AS; Krüger S; Hedderich J; Rompel R; Haag J; Röcken C; Hauschild A
    J Mol Diagn; 2016 Jan; 18(1):75-83. PubMed ID: 26607775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma.
    Wong SQ; Behren A; Mar VJ; Woods K; Li J; Martin C; Sheppard KE; Wolfe R; Kelly J; Cebon J; Dobrovic A; McArthur GA
    Oncotarget; 2015 Jan; 6(2):1115-27. PubMed ID: 25544760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.